Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason J Luke

Showing results (51-60 of 185) with videos related to

Pageof 19
Sort By:
Journal for Immunotherapy of Cancer|January 8, 2019
Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodiesChristopher C Frohne, Ernesto M Llano, Ashley Perkovic, et al.
Frontiers in Immunology|April 8, 2021
Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac AllograftAmy E Goodman, Lilit Karapetyan, Melissa Pugliano-Mauro, et al.
Immunological Reviews|July 30, 2019
STING pathway agonism as a cancer therapeuticBlake A Flood, Emily F Higgs, Shuyin Li, et al.
Melanoma Research|February 7, 2018
Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridizationMasahiko Yanagita, Jason J Luke, Frank S Hodi, et al.
Journal for Immunotherapy of Cancer|February 9, 2022
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapyRyan C Augustin, Robert D Leone, Aung Naing, et al.
Melanoma Research|February 16, 2013
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011Jason J Luke, Lawrence V Rubinstein, Gary L Smith, et al.
Practical Radiation Oncology|October 4, 2021
Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT)Annie Xiao, Jason J Luke, Julien Partouche, et al.
Cancer Immunology Research|September 18, 2016
Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell TumorsShalin Shah, James E Ward, Riyue Bao, et al.
Journal for Immunotherapy of Cancer|March 15, 2020
A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumabDaniel J Olson, Padma Rajagopal, Melissa Y Tjota, et al.
Journal of Applied Clinical Medical Physics|February 24, 2021
Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS)Michelle B Rokni, Kelli B Pointer, Jonathan George, et al.
Pageof 19

Showing results (51-60 of 185) with videos related to

Sort By:
Pageof 19
Journal for Immunotherapy of Cancer|January 8, 2019
Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodiesChristopher C Frohne, Ernesto M Llano, Ashley Perkovic, et al.
Frontiers in Immunology|April 8, 2021
Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac AllograftAmy E Goodman, Lilit Karapetyan, Melissa Pugliano-Mauro, et al.
Immunological Reviews|July 30, 2019
STING pathway agonism as a cancer therapeuticBlake A Flood, Emily F Higgs, Shuyin Li, et al.
Melanoma Research|February 7, 2018
Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridizationMasahiko Yanagita, Jason J Luke, Frank S Hodi, et al.
Journal for Immunotherapy of Cancer|February 9, 2022
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapyRyan C Augustin, Robert D Leone, Aung Naing, et al.
Melanoma Research|February 16, 2013
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011Jason J Luke, Lawrence V Rubinstein, Gary L Smith, et al.
Practical Radiation Oncology|October 4, 2021
Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT)Annie Xiao, Jason J Luke, Julien Partouche, et al.
Cancer Immunology Research|September 18, 2016
Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell TumorsShalin Shah, James E Ward, Riyue Bao, et al.
Journal for Immunotherapy of Cancer|March 15, 2020
A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumabDaniel J Olson, Padma Rajagopal, Melissa Y Tjota, et al.
Journal of Applied Clinical Medical Physics|February 24, 2021
Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS)Michelle B Rokni, Kelli B Pointer, Jonathan George, et al.
Pageof 19